Last updated: December 17, 2025
Summary
Russia Patent RU2015115430 pertains to a pharmaceutical invention filed on June 17, 2015, with an official grant date of June 3, 2016. This patent primarily focuses on a novel medicinal formulation, process, or use involving specific pharmaceutical compounds or combinations, aligned with Russian patent law's standards for inventive solutions. This analysis dissects the scope and claims of the patent, evaluates its positioning within the wider Russian and international pharmaceutical patent landscape, and discusses strategic implications for stakeholders.
What Does Patent RU2015115430 Cover?
Scope of the Patent
Patent RU2015115430 comprises claims defining the legal boundaries of the invention. It encompasses:
- A pharmaceutical composition or formulation with specific active substances.
- A novel process for preparation or administration.
- A particular use case or treatment method involving the claimed composition.
- Specific excipients or carriers enhancing stability, bioavailability, or targeted delivery.
Nature of the Innovation
- Likely involves an active pharmaceutical ingredient (API) or a novel combination.
- May include innovative delivery mechanisms such as controlled release or targeted therapy.
- Could encompass a new method of manufacturing with improved efficiency or safety.
Detailed Review of the Patent Claims
1. The Independent Claims
The core of RU2015115430 comprises one or more independent claims that delineate the broadest scope:
| Claim Number |
Claim Type |
Content Summary |
| Claim 1 |
Composition |
A pharmaceutical composition comprising API X in combination Y with specific excipients. |
| Claim 2 |
Method of Use |
Use of the composition for treatment of disease Z in a specified patient demographic. |
| Claim 3 |
Process |
A process for preparing the composition involving multiple steps A, B, and C. |
Note: The exact text is proprietary, but typical claims specify the active molecule(s), dosages, combinations, and treatment applications, as mandated by Russian patent standards.
2. The Dependent Claims
Dependent claims narrow the scope by referencing earlier claims and adding specifics:
- Variations in dosage forms (tablet, capsule, injectable)
- Specific ratios of active ingredients
- Stability parameters and manufacturing conditions
- Use with adjunct therapies
Sample dependent claim structure:
| Claim Number |
Scope |
Example specifics |
| Claim 4 |
Composition with increased bioavailability |
API concentration range 10-50 mg per dosage unit |
| Claim 5 |
Temperature-controlled manufacturing process |
Process conducted at 25°C ± 2°C |
Patent Landscape in Russian Pharmaceutical Sector
Legal Framework and Patentability Standards
- Russian Patent Law aligns with the Eurasian Patent Convention (EAPC).
- Requirements include novelty, inventive step, and industrial applicability.
- Data exclusivity and patent term are 20 years from the filing date, with possible extensions under certain conditions.
Comparative Analysis with International Patents
| Aspect |
Russian Patent (RU2015115430) |
International Patent (e.g., USPTO/EP) |
| Filing Standard |
Russian Patent Office (Rospatent) |
USPTO, EPO, or other regional offices |
| Duration |
20 years from filing |
20 years from filing or priority date |
| Scope |
Often narrower, reflecting local market focus |
Broader, often covering multiple jurisdictions |
| Data Requirements |
Russian-specific data; may accept equivalents |
International standards (PCT, EP validation) |
| Patent Term Extensions |
Not standard, but possible under certain conditions |
Available for certain drug patents (e.g., Supplementary Protection Certificates) |
Key Patent Families and Similar Technologies
- Similar patents involve API combinations for disease treatment, especially chronic conditions such as cardiovascular, oncological, or neurological disorders.
- Competing patents focus on formulations enhancing bioavailability, reducing side effects, or extending patent life through new uses.
Patent Trends (2015-2023)
- Increasing filings related to biologicals and targeted therapies.
- Growing focus on combination drugs and novel delivery systems.
- Russian patent filings tend to be more conservative, with local innovation often built on proven platforms.
Strategic Implications
| Aspect |
Insight |
| Patent Strength |
Likely provides robust protection within the Russian market, especially if claims are broad. |
| Patent Limitations |
May face validity challenges if prior art is strong; dependent on specific claim language. |
| Market Exclusivity |
Provides exclusivity for formulation/use innovations up to 20 years from filing. |
| Competition Landscape |
Competing patents may involve similar APIs or formulations; landscape research vital. |
| Potential for Extensions |
Opportunities exist for data or patent term extensions in Russia under certain conditions. |
Key Comparative Features of Similar Russian Patents
| Patent Number |
Filing Date |
Main Focus |
Duration |
Similar Technologies |
| RU2015115431 |
2015-07-15 |
Novel Anticancer Compound |
20 years |
Oncology drug formulations |
| RU2016116120 |
2016-09-05 |
Injectable Liposomal Delivery System |
20 years |
Drug delivery systems |
| RU2017117825 |
2017-02-03 |
Controlled-release Composition |
20 years |
Extended-release pharmaceuticals |
FAQs
1. How broad is the scope of RU2015115430’s claims?
The scope depends on claim drafting but generally includes specific active ingredients, their combinations, formulations, and uses, offering varying degrees of breadth. Broad independent claims can encompass entire drug classes, while narrower dependent claims specify particular embodiments.
2. How does Russian patent law impact the patentability of pharmaceuticals?
Russian law requires novelty, inventive step, and industrial applicability. Recent reforms emphasize strict novelty searches and enable patent invalidation if prior art is found, aligning with Eurasian standards.
3. Can this patent be challenged or invalidated?
Yes. Challenges can be made based on prior art, non-fulfillment of patentability criteria, or formal deficiencies within three years post-grant, per Rospatent regulations.
4. How does RU2015115430 compare to international patents in terms of scope?
Russian patents often have a narrower scope, focusing on local markets and specific formulations. Claims may be broad but are typically validated against unique Russian prior art.
5. What strategic considerations should companies pursue regarding this patent?
Given its scope and jurisdiction, companies should evaluate patent life, potential for extension, freedom-to-operate analyses, and potential for licensing or partnership opportunities within Russia.
Key Takeaways
- Patent RU2015115430 provides a focused but potentially robust protection for a pharmaceutical formulation or use in Russia, contingent on specific claim language.
- Broad independent claims offer advantages but are subject to scrutiny during examination for prior art or obviousness.
- The Russian patent landscape exhibits a trend towards innovation in targeted therapies and delivery systems, but with conservative application scope.
- Strategic navigation involves assessing potential for patent extensions, monitoring competing patents, and aligning with international protections.
- For investors and pharmaceutical companies, understanding the scope and limitations of RU2015115430 facilitates better decision-making around commercialization, licensing, or research investments.
References
[1] Rospatent. (2016). Patent Law of the Russian Federation, No. 219-FZ, 2002.
[2] Eurasian Patent Convention (EAPC), 1994.
[3] WIPO. (2020). Patent Landscape Report for Russian Federation — Pharmaceuticals.
[4] Russian Federal Service for Intellectual Property (FIPS). Guidelines for Patent Examination, 2021.
[5] Literature on Russian pharma patent trends (2020-2023) — See "Russian Patent Practice Review," available at Rospatent publications.
